Allgayer H, Kruis W, Eisenburg J, Paumgartner G
Eur J Clin Pharmacol. 1984;26(2):275-7. doi: 10.1007/BF00630300.
Rectal administration of sulphasalazine to patients with ulcerative colitis has recently been shown to have similar therapeutic activity but fewer side effects than oral treatment. The present study is a comparison of the pharmacokinetics of sulphasalazine (SASP) and its metabolite sulphapyridine (SP) after rectal and oral administration of SASP to 6 patients with ulcerative colitis. The areas under the concentration-time curves (AUC) and the maximum concentrations (Cmax) of SASP and SP were significantly lower after rectal than oral administration of SASP (p less than 0.05). These findings support the view that the lower frequency of side effects after rectal administration of SASP may result from the lower plasma levels of SASP and SP.
最近研究表明，对溃疡性结肠炎患者直肠给药柳氮磺胺吡啶，其治疗活性与口服治疗相似，但副作用更少。本研究比较了6例溃疡性结肠炎患者直肠和口服柳氮磺胺吡啶（SASP）后，柳氮磺胺吡啶（SASP）及其代谢产物磺胺吡啶（SP）的药代动力学。直肠给药SASP后，SASP和SP的浓度-时间曲线下面积（AUC）和最大浓度（Cmax）显著低于口服给药（p小于0.05）。这些发现支持以下观点：直肠给药SASP后副作用发生率较低，可能是由于SASP和SP的血浆水平较低所致。
